IDH2 and central nervous system cancer: Both IDH and TERTp mutations dominated in lower‐grade gliomas, and only TERTp mutations dominated in higher‐grade gliomas (Figure 1), which is consistent with the better prognosis of lower‐grade gliomas and the worse prognosis of higher‐grade gliomas.